Dr. Finn on the Revolution of CDK4/6 Inhibition in HR+ Breast Cancer

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

The field has changed quickly in a short period of time after decades of limited novel approaches in this particular space, Finn explains, adding that there are now 3 CDK4/6 inhibitors approved. These agents included palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). All of the clinical trials exploring these drugs demonstrate similar efficacy findings and a bit overlapping toxicities; however, each molecule has unique aspects.

To date, there are 6 randomized clinical trials of these CDK4/6 inhibitors reading out over the past 1 to 2 years, which have helped to evolve the field of breast cancer, Finn says.

<<< View more from the 2017 Chemotherapy Foundation Symposium